Did You Know?

Editor’s Picks

Latest News

Secarna Pharmaceuticals and Denali Therapeutics Enter Into Research and Option Agreement to Develop Novel Antisense Therapies in the Field of Neurodegenerative Diseases

Companies will leverage Secarna's industry-leading antisense oligonucleotide (ASO) discovery and development platform LNAplusTM and Denali's blood-brain barrier technology to discover...

error: Content is protected !!